1st Announcement and Call for Abstracts

Abstract Submission Opens: January 14, 2015
Online Registration & Housing Opens: January 14, 2015
Abstract Submission Deadline: April 15, 2015
Abstract Notifications: June 22, 2015
Early Registration Deadline: June 26, 2015
Late-Breaking Abstract Submission Deadline: June 30, 2015
Regular Registration Deadline: July 24, 2015

SEPTEMBER 6–9, 2015
DENVER, COLORADO, USA

BECOME A MEMBER OF IASLC
VISIT WWW.IASLC.ORG

WWW.IASLC.ORG

JOIN US FOR THE 16TH WORLD CONFERENCE ON LUNG CANCER
DENVER 2015!
The next World Conference on Lung Cancer (WCLC) will take place September 6 – 9, 2015 in Denver, CO, USA.

It is a great pleasure for us to invite you to the World Conference and to Denver, the “Mile High City”. While much encouragement and progress is going on these days in the lung cancer field, both with screening as well as treatment, the disease is still a huge global health problem. The Conference will address all aspects from tobacco policy/prevention to biology and treatment progress of all stages of lung cancer.

Denver is a smart, vibrant city with 300 days of sunshine. From the new History Colorado Center, the always amazing Denver museum of Nature & Science to the mile-long pedestrian promenade, lined with fine dining, shopping and a lively nightlife — your opportunities are endless in Denver. There is also a world of adventure waiting to be discovered in the Rocky Mountains, just a short drive from Denver.
WHO SHOULD ATTEND?

The 16th World Conference on Lung Cancer will be one of the largest international gatherings of clinicians and scientists in the field of lung cancer and thoracic malignancies.

Those interested in all aspects of lung cancer including surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists are encouraged to attend this Conference.

Also, the Conference will continue implementing special sessions for nurses, allied health professional and advocacy members.

Based on the success of previous Conferences, more than 9,000 delegates from all around the world are expected to attend. We are looking forward to a program covering a wide range of disciplines including more than 300 invited talks and 3,000 scientific abstracts presented in Oral, Mini Oral and Poster Sessions.

We will continue with the extraordinarily successful Hands-On Training Sessions and the Young Investigator Session to provide young investigators and other physicians in early stages of their career with the opportunity to receive one-on-one guidance from leading international experts.

We welcome you to an inspiring, educational, and enjoyable program.
CONFERENCE COMMITTEES

LOCAL ORGANIZING COMMITTEE

President
Fred R. Hirsch
University of Colorado

Co-Chairs
James Jett
National Jewish Health
Harvey Pass
NYU Langone Medical Center
Everett Vokes
The University of Chicago Medicine

Committee
Dara Aisner,
University of Colorado
Anna Baron,
University of Colorado
Paul A. Bunn, Jr.,
University of Colorado
Tim Byers,
University of Colorado
D. Ross Camidge,
University of Colorado
Laurie Carr,
National Jewish Health
Robert Doebele,
University of Colorado
Wilbur Franklin,
University of Colorado
Marileila Varella-Garcia,
University of Colorado
Kavita Garg,
University of Colorado
Laurie Gaspar,
University of Colorado
Robert Jotte,
Rocky Mountain Cancer Centers
Brian Kavanagh,
University of Colorado
Robert Keith,
University of Colorado
Jeffrey Kern,
National Jewish Health
Evi Makovsky,
Patient Advocate
Dan Merrick,
University of Colorado
York Miller,
University of Colorado
John Mitchell,
University of Colorado
Ana Oton,
University of Colorado
David Raben,
University of Colorado
Michael Weyant,
University of Colorado
Samir Witta,
Mountain Blue Cancer Care Center

CORE PROGRAM COMMITTEE

SCIENCE TRACKS

Treatment of Advanced Disease - NSCLC
Ross Camidge, USA (Chair)
Glenwood Goss, Canada (Co-Chair)
Michael Boyer, Australia
Julie Brahmer, USA
Brian Kavanagh, USA
Peter Meldgaard, Denmark
Silvia Novello, Italy
Solange Peters, Switzerland
Robert Pirker, Austria
Kenneth Rosenzweig, USA
Lecia Sequist, USA
Alice Shaw, USA
Ross Soo, Singapore
James Spicer, UK
Yi-Long Wu, China
Yasushi Yatabe, Japan

Treatment of Localized Disease - NSCLC
Michael Weyant, USA (Chair)
Hisao Asamura, Japan (Co-Chair)
Anna Baron, USA
Paul de Leyn, Belgium
Jessica Donington, USA
Rafal Dziadziuszko, Poland
Simon Ekman, Sweden
Wilbur Franklin, USA
Ramanswamy Govindan, USA
David Harpole, USA
John Mitchell, USA
Bernward Passlick, Germany
Umbrerto Ricardi, Italy
Ales Ryska, Czech Republic
Pascal Thomas, France
Eric Vallieres, USA
Luhua Wang, China

Treatment of Locoregional Disease - NSCLC
Everett Vokes, USA (Chair)
Wilfried Eberhardt, Germany (Co-Chair)
David Ball, Australia
Hak Choy, USA
Walter Curran Jr., USA
Pilar Garrido, Spain
Laurie Gaspar, USA
Felix Herth, Germany
Kemp Kernstine, USA
Feng-Ming (Spring) Kong, USA
Keunchil Park, South Korea
Suresh Senan, Netherlands
Georgios Stamatis, Germany
Craig Stevens, USA
Masahiro Tsuboi, Japan
Walter Weder, Switzerland
Junji Yoshida, Japan

**Biology, Pathology, and Molecular Testing**
Robert Doebele, USA (Chair)
Andrew Nicholson (Co-Chair)
Dara Aisner, USA
David G. Beer, USA
Martin Filipits, Austria
Adi F. Gazdar, USA
Peter Hammerman, USA
Tetsuya Mitsudomi, Japan
Nick Pavlakis, Australia
David Raben, USA
Ravi Salgia, USA
Dara Aisner, USA
David G. Beer, USA
Martin Filipits, Austria
Adi F. Gazdar, USA
Peter Hammerman, USA
Tetsuya Mitsudomi, Japan
Nick Pavlakis, Australia
David Raben, USA
Ravi Salgia, USA

**Prevention and Tobacco Control**
James Jett, USA (Chair)
Pan-Chyr Yang, Taiwan
(Co-Chair)
Tim Byers, USA
Michael Cummings, USA
Carolyn Dresler, USA
Nasser Hanna, USA
Surender Kashyap, India
Robert Keith, USA
Stephen C. Lam, Canada
Charles A. Powell, USA
Jonathan Samet, USA
Nico van Zandwijk, Australia
Ping Yang, USA

**Screening and Early Detection**
York Miller, USA (Chair)
John Field, UK (Co-Chair)
Raja Flores, USA
Kwun Fong, Australia
Kavita Garg, USA
Ryutaro Kakinuma, Japan
Jeffrey Kern, USA
Annette McWilliams, Australia
Daniel Merrick, USA
Stefan Michiels, France
James Mulshine, USA
Nir Peled, Israel
Pieter Postmus, Netherlands
Helmut Prosch, Austria
Gerald Schmid-Bindert, Germany
Giulia Veronesi, Italy
David Yankelevitz, USA

**Small Cell Lung Cancer**
Paul A. Bunn, Jr., USA (Chair)
Martin Reck, Germany
(Co-Chair)
Odd Terje Brustugun, Norway
Federico Cappuzzo, Italy
Gail Darling, Canada
Corinne FAivre-Finn, UK
Jacek Jassem, Poland
Keith Kerr, UK
Cécile Le Péchoux, France
Eric Lim, UK
John Minna, USA
Charles Rudin, USA
Frances Shepherd, Canada
Yu Shyr, USA
Miguel Villalona, USA
James Chih-Hsin Yang, Taiwan
Caicun Zhou, China

**Thymoma, Mesothelioma, Other Thoracic Malignancies**
Harvey Pass, USA (Chair)
Paul Baas, Netherlands
(Co-Chair)
Benjamin Besse, France
Raphael Bueno, USA
Marc de Perrot, Canada
Frank Detterbeck, USA
Dean Fennell, UK
Pier Luigi Filosso, Italy
Nicolas Girard, France
Thierry Jahan, USA
Hedy Lee Kindler, USA
Loic Lang-Lazdunski, UK
Takashi Nakano, Japan
Anna Nowak, Australia
Yoshitaka Sekido, Japan
Charles Thomas, USA
Jan Van Meerbeek, Belgium
Benny (Chung-ying) Zee, China

**Nursing and Allied Professionals**
Mary Hesdorffer, USA (Chair)
Jesme Fox, UK (Co-Chair)
Suk-Chul Bae, South Korea
Carolyn Clary-Macy, USA
Laurie Gaspar, USA
Fred R. Hirsch, USA
Keith Kerr, UK
York Miller, USA
Tony Mok, China
Françoise Mornex, France
Harvey Pass, USA
Robert Pirker, Austria
Benjamin Solomon, Australia
Paul van Schil, Belgium
Kostas N. Syrigos, Greece
Federico Venuta, Italy
Everett Vokes, USA
Yasuishi Yatabe, Japan
Caicun Zhou, China

**Advocacy**
Glenda Colburn, Australia (Chair)
Kim Norris, USA (Co-Chair)
Bonnie Addario, USA
Carolyn Aldige, USA
Laurie Fenton-Ambrose, USA
Andrea Ferris, USA
Evi Makovsky, USA

**Palliative and Supportive Care**
Ana Oton, USA (Chair)
Vera Hirsh, Canada (Co-Chair)
Sam Ahmedzai, UK
Raphael Catane, Israel
David Currrow, Australia
Anne Fraser, New Zealand
Richard Gralla, USA
Pyng Lee, Singapore
Alex Molasios, China
Gerard Silvestri, USA
Berend Slotman, Netherlands
Darcey Sypolt, USA
Paul van Houtte, Belgium

**EDUCATION TRACKS**

**Best of WCLC**
David R. Gandara, USA (Chair)
Roy Herbst, USA (Co-Chair)
Paul A. Bunn, Jr., USA
Laurie Gaspar, USA
Fred R. Hirsch, USA
Keith Kerr, UK
York Miller, USA
Tony Mok, China
Françoise Mornex, France
Harvey Pass, USA
Robert Pirker, Austria
Benjamin Solomon, Australia
Paul van Schil, Belgium
Kostas N. Syrigos, Greece
Federico Venuta, Italy
Everett Vokes, USA
Yasuishi Yatabe, Japan
Caicun Zhou, China

**Community Practices**
Edward Kim, USA (Chair)
David Spigel, USA (Co-Chair)
Richard Booton, UK
Laurie Carr, USA
Thomas D’Amico, USA
Thomas A. Hensing, USA
Robert Jotte, USA
Patricia Kho, Singapore
Raymond Osarogiabon, USA
Craig Reynolds, USA
Kostas N. Syrigos, Greece
Marileila Varella-Garcia, USA
Virginie Westeel, France
Samir Witta, USA
Gail Wright, USA
LEARNING OBJECTIVES

At the end of the Conference the attendee will be able to:

- Identify effective global lung cancer prevention strategies.
- Improve their ability to participate in tobacco control and smoking cessation programs.
- Describe the current approaches and strategies for early detection and screening of lung cancer.
- Describe the best methods to implement multi-disciplinary tumor boards into community practices.
- Describe evidence-based therapeutic regimens for early stage and locally advanced NSCLC.
- Describe evidence-based therapeutic regimens for metastatic NSCLC based on biomarker status and patient/tumor characteristics.
- Integrate clinical data on maintenance therapy in NSCLC to determine which patients would benefit most from a maintenance regimen.
- Recognize the clinical significance of optimal biopsy, specimen flow and molecular testing for personalized medicine in non-academic settings.
- Understand the molecular pathways that hold promise for therapeutic intervention.
- Outline current therapeutic approaches for limited and extensive small cell lung cancer (SCLC).
- Describe current therapeutic approaches for patients with mesothelioma and thymoma.
- Define optimal and best practice approaches for supportive and palliative care of patients with thoracic cancers.
- Describe the support and survivorship resources available for lung cancer patients and their families.
- Illustrate important aspects of clinical trial design and master protocols.
- Educate more junior investigators and students on research and technology advances, and encourage them to initiate investigations in lung cancer research.
ACCREDITATION

CME Accreditation

This activity is planned for AMA PRA Category 1 Credit(s)™. Please visit the Conference website at www.iaslc.org for further information.

GOALS

Lung Cancer is the leading cause of death worldwide. Despite intensive research efforts to discover more effective treatment regimens, the survival rates for lung cancer remain low. However, data from lung cancer research continue to emerge, with the identification of genetic mutations and the developments of molecularly targeted agents that can help usher in the era of personalized lung cancer treatment. The World Conference on Lung Cancer provides a forum for the dissemination of the latest research findings to help physicians and researchers in lung cancer remain current on the optimum treatment approaches for individuals with lung cancer, as well as on issues related to prevention, early detection, imaging, staging according to the new IASLC staging system, and palliative care. The World Conference also addresses the importance of tobacco control in reducing the morbidity and mortality associated with lung cancer.

UNLABELED USAGE STATEMENTS

The information presented at the World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

OFFICIAL LANGUAGE

The official language of the 16th World Conference on Lung Cancer is English.
SESSION OVERVIEW

EDUCATIONAL SESSIONS
These sessions offer multidisciplinary exploration of focused topics related to thoracic oncology. Particular care will be taken to ensure that these sessions are integrated in terms of such issues as surgical, radiation, and medical oncology; symptom management; health services research; global perspectives; and pathology, as appropriate.

HIGHLIGHTS OF THE DAY SESSIONS
In these sessions, experts in the field will summarize the essence of selected abstracts of clinical/translational research presented on the previous day.

INTERACTIVE GRAND ROUNDS SESSIONS
These sessions invite active participation of audience. After a brief introductory lecture, a typical case scenario will be presented for discussion with a series of questions for the audience to answer.

MEET THE EXPERT SESSIONS (MTE – TICKETED SESSIONS)
These sessions provide open discussion between recognized experts and session attendees, with an opportunity for attendees to interact personally with the experts.
(Not included in registration, additional fees apply. Limited capacity.)

MINI SYMPOSIA SESSIONS
In these sessions, reports on the latest scientific results, controversial issues, and emerging concepts will be presented. Experts in the field place the studies in the appropriate context based on the strength of the evidence and critically discuss the conclusions in terms of their applicability to clinical practice.
PLENARY SESSIONS AND PRESIDENTIAL SYMPOSIUM

In Plenary sessions, several lectures which are of particular interest, importance, and relevance to attendees, will be presented. Top-scoring abstracts selected by the Scientific Committee will be presented in the Presidential Symposium on Tuesday, September 8.

ORAL (ABSTRACT) SESSIONS

These sessions include 10-minute didactic presentations of selected abstracts of scientific research in clinical trials, basic and translational research by topics. Experts in the field serve as discussants to place research findings into perspective.

MINI ORAL (ABSTRACT) SESSIONS

Selected papers will be presented in short 3 – 5 minute presentations in Mini Oral Sessions and then discussed by leading experts who will summarize the finding of those papers including a commentary on the research and outcomes.

POSTER SESSIONS

Multiple abstracts will be selected for Poster presentations. Posters will be on display in the Exhibit Hall. Presenting Authors of these posters are asked to stand by their posters at a specified time to explain their research and answer questions from delegates.

YOUNG INVESTIGATOR’S AND FIRST TIME ATTENDEE SESSION

The Young Investigator’s Session, which is designed specifically for medical professionals in training and those in the early stages of their career, will provide a unique opportunity to interact with recognized leaders in the field of thoracic oncology. The session will also provide practical, treatment-oriented, and career-related information as well as important Conference information for first time attendees.

INDUSTRY SUPPORTED SYMPOSIA

Industry Supported Symposia will be offered to Conference attendees free of charge. These will be sponsored by a variety of companies. Topics will be chosen after consultation with the Core Program Committee and will compliment the scientific sessions of the Conference.

EXHIBIT SHOWCASE SESSIONS

During the morning and afternoon networking as well as the lunch breaks, the Conference will offer Exhibit Showcase Sessions free of charge. These will be sponsored by a variety of companies and take place in the Exhibit Showcase Theater in the Exhibit Hall.
<table>
<thead>
<tr>
<th>TUESDAY  →  SEPTEMBER 8, 2015</th>
<th>WEDNESDAY  →  SEPTEMBER 9, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LUNG CANCER: A WOMEN’S DISEASE</strong></td>
<td><strong>SCIENCE DRIVES LUNG CANCER ADVANCES</strong></td>
</tr>
<tr>
<td><strong>FUN RUN</strong></td>
<td><strong>MTE SESSIONS (TICKETED SESSIONS)</strong></td>
</tr>
<tr>
<td><strong>MTE SESSIONS (TICKETED SESSIONS)</strong></td>
<td><strong>MTE SESSIONS (TICKETED SESSIONS)</strong></td>
</tr>
<tr>
<td><strong>OPPOSED INDUSTRY SYMPOSIA</strong></td>
<td><strong>OPPOSED INDUSTRY SYMPOSIA</strong></td>
</tr>
<tr>
<td><strong>HIGHLIGHTS OF PRIOR DAY</strong></td>
<td><strong>HIGHLIGHTS OF PRIOR DAY</strong></td>
</tr>
<tr>
<td><strong>PRESIDENTIAL SYMPOSIUM INCLUDING TOP 4 ABSTRACTS</strong></td>
<td><strong>PLENARY SESSION</strong></td>
</tr>
<tr>
<td><strong>NETWORKING BREAK AND POSTER SESSION</strong></td>
<td><strong>NETWORKING BREAK AND POSTER SESSION</strong></td>
</tr>
<tr>
<td><strong>PRESS CONFERENCE</strong></td>
<td><strong>PRESS CONFERENCE</strong></td>
</tr>
<tr>
<td><strong>ABSTRACT SESSIONS (ORAL AND MINI ORAL SESSIONS)</strong></td>
<td><strong>ABSTRACT SESSIONS (ORAL AND MINI ORAL SESSIONS)</strong></td>
</tr>
<tr>
<td><strong>UNOPPOSED INDUSTRY SUPPORTED SYMPOSIUM</strong></td>
<td><strong>UNOPPOSED INDUSTRY SUPPORTED SYMPOSIUM</strong></td>
</tr>
<tr>
<td><strong>INVITED SESSIONS (EDUCATIONAL SESSIONS, MINI SYMPOSIUM, GRAND ROUNDS, ETC.)</strong></td>
<td><strong>INVITED SESSIONS (EDUCATIONAL SESSIONS, MINI SYMPOSIUM, GRAND ROUNDS, ETC.)</strong></td>
</tr>
<tr>
<td><strong>NETWORKING BREAK AND POSTER SESSION</strong></td>
<td><strong>NETWORKING BREAK AND POSTER SESSION</strong></td>
</tr>
<tr>
<td><strong>ABSTRACT SESSIONS (ORAL AND MINI ORAL SESSIONS)</strong></td>
<td><strong>ABSTRACT SESSIONS (ORAL AND MINI ORAL SESSIONS)</strong></td>
</tr>
<tr>
<td><strong>UNOPPOSED INDUSTRY SUPPORTED SYMPOSIUM</strong></td>
<td><strong>UNOPPOSED INDUSTRY SUPPORTED SYMPOSIUM</strong></td>
</tr>
<tr>
<td><strong>GALA DINNER (TICKETED EVENT)</strong></td>
<td><strong>CLOSING PLENARY SESSION</strong></td>
</tr>
<tr>
<td><strong>CLOSING REMARKS</strong></td>
<td></td>
</tr>
</tbody>
</table>

Program listings are subject to change.
CALL FOR ABSTRACTS

The Core Program and Local Organizing Committee for the 16th World Conference on Lung Cancer are inviting the submission of scientific abstracts. Authors are asked to submit abstracts under one of the following categories:

- Treatment of Advanced Disease – NSCLC
- Treatment of Localized Disease – NSCLC
- Treatment of Locoregional Disease – NSCLC
- Biology, Pathology, and Molecular Testing
- Prevention and Tobacco Control
- Screening and Early Detection
- Small Cell Lung Cancer
- Thymoma, Mesothelioma, and Other Thoracic Malignancies
- Nursing and Allied Professionals
- Advocacy
- Palliative and Supportive Care

CLINICAL TRIALS IN PROGRESS

The Conference will also accept submissions of abstracts on Clinical Trials in Progress. Submitters of such abstracts are asked to submit their abstract under the most appropriate category.

CONTACT

For more information, please visit the Conference website at www.iaslc.org. For any inquiries, please contact pia.hirsch@iaslc.org.

ABSTRACT SUBMISSION OPENS ➔ JANUARY 14, 2015
ABSTRACT SUBMISSION DEADLINE ➔ APRIL 15, 2015

ABSTRACT DEADLINES

<table>
<thead>
<tr>
<th>Abstract Submission Opens</th>
<th>January 14, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract Submission Deadline</td>
<td>April 15, 2015</td>
</tr>
<tr>
<td>Author Notification of Acceptance</td>
<td>June 22, 2015</td>
</tr>
<tr>
<td>Late-Breaking Abstract Submission Deadline</td>
<td>June 30, 2015</td>
</tr>
<tr>
<td>Presenting Author Registration Deadline</td>
<td>July 17, 2015</td>
</tr>
</tbody>
</table>

CLINICAL TRIALS IN PROGRESS

The Conference will also accept submissions of abstracts on Clinical Trials in Progress. Submitters of such abstracts are asked to submit their abstract under the most appropriate category.

CONTACT

For more information, please visit the Conference website at www.iaslc.org. For any inquiries, please contact pia.hirsch@iaslc.org.
SUBMISSION GUIDELINES

- Research work should be original and innovative. Work can be presented prior to the 16th WCLC, but MUST include new information/data
- Abstracts must be submitted electronically through the Conference website
- Abstracts will be accepted in English only
- Abstracts should not exceed 500 words in length (not including title and authors)
- Abstract title should not exceed 20 words
- Tables may be included and each will count as 100 words
- A maximum of 2 images may be included; each will count as 100 words
- Abstracts must be structured with the following. Each section must be completed.
  - Background
  - Methods
  - Results
  - Conclusion
- The presenting author of an accepted abstract must be registered by July 17, 2015
- There is no fee for submitting an abstract
- There is no limit to the number of co-authors per abstract
- There is no limit to the number of abstracts you may submit (however an individual may not be offered more than 2 oral presentations)
- An international panel of reviewers will review all abstracts anonymously
- All Abstracts accepted by the Scientific Committee will be published in the Journal of Thoracic Oncology (JTO) and the Conference website prior to the meeting and it is mandatory to agree to this at the time of submission
- Financial Disclosure information needs to be completed for EACH co-author at the time of submission through the online abstract submission form; however, information can be provided by the submitting author

LATE-BREAKING ABSTRACT SUBMISSION

The WCLC 2015 will offer Late-Breaking Abstract submission only for:

- Randomized Phase II and III studies trials with no preliminary data available at the time of the abstract submission deadline (April 15, 2015) but where a preplanned analysis of the primary endpoint is scheduled before June 30, 2015 (deadline for the final, updated Late-Breaking Abstract). During abstract submission you will be required to provide the date of planned analysis.
- Large observation studies of over 1,000 patients.
- Major biological discoveries or break-throughs recently accepted but not yet published in top-ranked journals.

In order for an abstract to be considered for Late-Breaking Abstract status, the submitting author must submit a placeholder abstract before the April 15, deadline. The results and conclusion can be omitted but the type of data that will be presented in the Late-Breaking Abstract must be described as well as why Late-Breaking status is required.

If your study meets any of the above criteria and you wish to apply for Late-Breaking privileges, you must submit an abstract by the regular submission deadline April 15, 2015. To apply for Late-Breaking privileges you must send an email to wclc2015@icsevents.com, indicating your abstract ID number and explaining why data is not yet available and when you expect it to become available. The Core Program Committee will then review your abstract and application. If your application is approved you will be notified and instructed on how to submit your new data by June 16, 2015.
SCHOLARSHIPS

Scholarships are available for Young Investigators (35 years of age or younger) and Developing Nations Investigators (as defined by the IASLC Membership Guidelines). These awards will consist of complimentary registration to the conference, up to four (4) night’s accommodation, a fixed amount to cover travel expenses and free membership in the IASLC for one year.

If you fulfill all criteria for both awards, you may apply for both; however, if selected, you will only be offered one award.

Supporting Materials for Young Investigator Award (35 years of age or younger)
- Proof of age
- Curriculum Vitae
- Statement by the senior member (who must be a member of IASLC) of the candidate’s role in the research

Supporting Materials for Developing Nation Award (Developing Nation as defined by the IASLC Membership Guidelines)
- Curriculum Vitae
- Description of your interest and current research in lung cancer (1 – 5 pages)

CONTACT

For more information, please visit the Conference website at www.iaslc.org. For any inquiries, please contact pia.hirsch@iaslc.org.
IASLC INTERNATIONAL MENTORSHIP PROGRAM

About the program

The International Mentorship Program is a professional development and education program for early-career physicians/researchers studying thoracic malignancies from economically-developing countries*. The awardees are matched with well-established scientific and clinical mentors from within the hosting WCLC region and visit the mentor’s institution for approximately a week following the WCLC.

Goal of the Program

Share information and ideas and teach skills that the awardee can pass along to his or her colleagues at their home institutions. Establish communication and collaborative relationships between the mentor and mentee, and their respective institutions.

APPLICANT ELIGIBILITY

1. From an economically-developing nation as defined by the IASLC Membership Guidelines*.
2. Less than 5 years since start of MD fellowship or PhD postdoctoral training or equivalent training based on home country.
3. Submitted an abstract to the WCLC.

SUPPORTING MATERIALS

- Application
- Biographical Sketch
- Summary of scientific and clinical interests
- Copy of abstract submitted to WCLC
- Personal statement on goals and how this award will help reach those goals
- Two letters of recommendation

*Currently corresponds to the World Bank list of countries in the following income groups: low income, lower middle income and upper middle income, or those countries where GNI per capita is US$12,476 or less. List of countries is available at www.iaslc.org/countries.

HOW TO APPLY FOR A SCHOLARSHIP OR THE IASLC INTERNATIONAL MENTORSHIP PROGRAM

1. The candidate must be the first author and presenter of the submitted abstract

2. Abstract must be submitted on or before the submission deadline April 15, 2015 via the online abstract submission form

3. Candidate must apply at the time of abstract submission and provide the outlined supporting materials via email to the Conference Secretariat at wclc2015@icsevents.com

The deadline for submission of these documents is April 15, 2015. Application materials received after April 15, 2015 or applications received without supporting materials cannot be considered.
REGISTRATION INFORMATION

REGISTRATION OPENS JANUARY 14, 2015

DISCOUNTED RATES WILL BE AVAILABLE FOR ALL IASLC MEMBERS.
SAVE UP TO 300 USD ON REGISTRATION FEES AND SIGN UP TO BECOME A MEMBER OF IASLC TODAY!

Registration fees and further information will be available on the Conference website at www.iaslc.org by September 1, 2014.
ACCOMMODATION INFORMATION

ACCOMMODATION BOOKINGS CAN BE MADE AT THE TIME OF REGISTRATION (OPENING JANUARY 14, 2015)

The Conference Secretariat (International Conference Services) is the official housing bureau for the 16th World Conference on Lung Cancer and will offer assistance with the coordination of housing requirements for the Conference. Special room rates have been negotiated and will be available to Conference delegates only.

The success of IASLC and WCLC depends on delegates, sponsors and exhibitors using the official Conference hotels by booking through the official housing bureau. IASLC/WCLC cannot meet contracted room obligations if registrants reserve rooms outside the official hotel. Rooms that are not filled because of that create an expense for the Association in the form of financial penalties (attrition fees) and place the financial success of the Conference and the Association at risk, which increases with each delegate who stays outside the Conference hotel or books the hotel through channels other than the official housing bureau.

SUPPORT IASLC... BOOK OFFICIAL!

DELEGATES BOOKING ACCOMMODATION THROUGH THE OFFICIAL HOUSING BUREAU WILL RECEIVE A REGISTRATION FEE DISCOUNT OF UP TO 100 USD.
CONTACT FOR REGISTRATION AND HOUSING

For any inquiries regarding Registration and Accommodation for the 16th WCLC, please contact our Registration and Housing Team at wclc2015-registration@icsevents.com.
## OFFICIAL CONFERENCE HOTELS

<table>
<thead>
<tr>
<th>HOTEL</th>
<th>STAR RATING</th>
<th>WALKING DISTANCE TO COLORADO CONVENTION CENTER</th>
<th>RATES*</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Hyatt Regency Denver (HQ)</td>
<td>★★★★★</td>
<td>Across from main entrance</td>
<td>$201 USD</td>
</tr>
<tr>
<td>B Crowne Plaza Denver</td>
<td>★★★★</td>
<td>5 minutes</td>
<td>$180 USD</td>
</tr>
<tr>
<td>C Denver Marriott City Center</td>
<td>★★★★</td>
<td>10 minutes</td>
<td>$199 USD</td>
</tr>
<tr>
<td>D Embassy Suites</td>
<td>★★★★</td>
<td>2 minutes</td>
<td>$209 USD</td>
</tr>
<tr>
<td>E Four Seasons Hotel</td>
<td>★★★★★</td>
<td>5 minutes</td>
<td>$215 USD</td>
</tr>
<tr>
<td>F Grand Hyatt Denver</td>
<td>★★★★</td>
<td>10 minutes</td>
<td>$190 USD</td>
</tr>
<tr>
<td>G Sheraton Denver Downtown Hotel</td>
<td>★★★★</td>
<td>9 minutes</td>
<td>$199 USD</td>
</tr>
<tr>
<td>H Ritz-Carlton Hotel</td>
<td>★★★★★</td>
<td>12 minutes</td>
<td>$215 USD</td>
</tr>
<tr>
<td>I Westin Denver Downtown</td>
<td>★★★★</td>
<td>11 minutes</td>
<td>$189 USD</td>
</tr>
<tr>
<td>J Brown Palace Hotel</td>
<td>★★★★★</td>
<td>11 minutes</td>
<td>$225 USD</td>
</tr>
<tr>
<td>K Magnolia Hotel Denver</td>
<td>★★★★</td>
<td>7 minutes</td>
<td>$199 USD</td>
</tr>
<tr>
<td>L Residence Inn by Marriott</td>
<td>★★★</td>
<td>9 minutes</td>
<td>$174 USD</td>
</tr>
<tr>
<td>M Comfort Inn Downtown</td>
<td>★★★</td>
<td>10 minutes</td>
<td>$139 USD</td>
</tr>
</tbody>
</table>

*Rates are for single occupancy in a standard room, excl. applicable tax.

## GROUPS OF 10 AND MORE (REGISTRATION AND/OR HOUSING)

If you have a group of 10 or more, please contact the Group Coordinator at wclc2015-groups@icsevents.com.
DENVER, COLORADO – THE MILE HIGH CITY

The City and Country of Denver is the largest city and capital of the US State of Colorado. Denver is also the second most populous county in Colorado, looking over the Great Plains just east of the majestic Rocky Mountains.

Denver is nicknamed the Mile-High City because its official elevation is exactly one mile or 5,280 feet (1,609.3m) above sea level, making it one of the highest major cities in the United States.

The City of Denver, Colorado has become a western vacation Mecca, hosting visitors from around the world. Rocky Mountain National Park is just an hour away and Colorado ski resorts are all within easy reach. Denver features lots of fun things to do for families, couples and singles including art galleries, museums, historic tours and loads of outdoor activities.

HOW TO GET THERE

Denver International Airport (DEN) is a major airline hub, the fifth busiest airport in the world and has non-stop service to destinations throughout North America, Latin America (e.g. Panama City), Europe (e.g. London, Frankfurt/Main, Reykjavik) and Asia (e.g. Tokyo Narita).

Since the airport opened in 1995, it has consistently won readers’ choice awards from publications like Business Traveler Magazine. The airport offers free wi-fi access in public areas and a diverse array of dining and shopping choices.

Located northeast of downtown Denver, a cab or shuttle ride puts you in the heart of the city in about 25 minutes. The city’s public transport system, Regional Transportation District (RTD), also operates five bus routes under the frequent airport express bus service called skyRide.

A cab ride from the airport to downtown is approximately 60 USD, but most cabs also accept credit cards.

CLIMATE

The average high in early September in Denver is 81 degrees Fahrenheit (27 degrees Celsius) and the average low is 54 degrees Fahrenheit (12 degrees Celsius).

SMOKING

Smoking is not permitted at the Conference facilities.

TIME ZONE

Denver is located in the Mountain Time Zone (GMT -7)

LOCAL INFORMATION
FACTS ABOUT DENVER

- Denver has a population of more than 634,000 (23rd most populous city in the USA)
- The mountainous area of Colorado is six times the size of Switzerland, containing 9,600 miles of fishing streams, 2,850 lakes, and more than 1,000 peaks two miles high
- Denver has more than 300 days of sunshine a year (more hours than Miami or San Diego)
- Denver is home to the largest city park system in the US with over 200 parks, 90 golf courses and 650 miles of paved trails
- Denver has one of the largest ‘Green Fleet’ programs in the nation with more than 50% of their public transportation fleet powered by alternatives

PASSPORT, VISA AND BORDER CROSSING INFORMATION

At the time of writing, to enter the USA, a valid passport is required for citizens of all countries. Visas are required for residents of certain countries; please contact your local US Embassy, Consulate or High Commission Office for the specific requirements for your country of origin (http://usembassy.state.gov/). For more information, please refer to: http://travel.state.gov/content/visas/english/visit/visitor.html

OFFICIAL AIRLINE NETWORK

Information regarding the Official Airline Network including discounts for travel to the 16th World Conference on Lung Cancer will be available on the Conference website.

LETTER OF INVITATION FOR VISA POLICY

An official Letter of Invitation to obtain a Visa and authorization to attend the 16th World Conference on Lung Cancer will be issued ONLY after registration has been completed and full payment received by the Conference Secretariat.

BANKS AND CURRENCY EXCHANGE

1 USD $ = 100 cents

Banks are generally open from 10:00 to 18:00, Monday through Friday. Automatic teller machines (ATMs) are found throughout Denver. International credit cards are accepted throughout the country at banks, hotels, resorts and the airport.

For up-to-date information, please refer to the Universal Currency Converter at: www.xe.com/ucc/
CONFERENCE VENUE

THE 16TH WORLD CONFERENCE ON LUNG CANCER WILL BE HELD AT THE COLORADO CONVENTION CENTER.

Colorado Convention Center
700 14th Street
Denver, CO 80202, United States
www.denverconvention.com

The Colorado Convention Center is located in the heart of the City of Denver, Colorado and features some of the best conference, exhibit, and event center space in the world. Opened in 1990, with more than 100 professional meeting planners working together with architects to design every aspect of the building, the result was simple; a sensible, state-of-the-art facility with easy traffic flow and everything you need in a stunningly beautiful building in the heart of downtown Denver. Expanded in 2005, well-known as one of the most practical and “user friendly” meeting facilities, the Colorado Convention Center is now home to over 250+ events annually. The Colorado Convention Center is located within easy walking distance of over 300 restaurants, 9 theatres of the Denver Performing Arts Complex and a wide variety of shopping and retail outlets.
IASLC CONFERENCE SECRETARIAT & HOUSING BUREAU

16th World Conference on Lung Cancer
c/o International Conference Services Ltd. (ICS)
Suite 2101 – 1177 West Hastings Street
Vancouver, BC, Canada V6E 2K3
Phone    +1 604 681 2153
Fax      +1 604 681 1049
Email    wclc2015@icsevents.com

THE LATEST INFORMATION AND UPDATES TO THIS 1ST ANNOUNCEMENT CAN BE FOUND ON THE 16TH WCLC WEBSITE AT WWW.IASLC.ORG
The 16th World Conference on Lung Cancer offers a tremendous opportunity to market to one of the largest international gatherings of researchers, clinicians and professionals in the field of lung cancer and thoracic oncology. Over 9,000 clinicians and scientists from around the world are expected to attend. Increase your visibility and organization’s profile by becoming a Sponsor and/or Exhibitor or by holding an Industry Supported Symposium at this outstanding and important Conference.

FOR MORE INFORMATION REGARDING SPONSORSHIP, SYMPOSIUM AND EXHIBIT OPPORTUNITIES, PLEASE CONTACT:

Pia Hirsch, International Association for the Study of Lung Cancer (IASLC)
pia.hirsch@iaslc.org
Phone: +1 720 325 2951
Fax: +1 720 325 2848

The Conference is pleased to offer a variety of sponsorship options, including but not limited to:

- Industry Supported Symposia
- Exhibit Showcase Sessions
- Hands-On Training Sessions
- Exhibit Space
- Signage Opportunities in and around the Colorado Convention Center
- Online and printed advertising opportunities
- Scholarship and Travel Grants
- Virtual and online conference components
- Hotel Key Cards
- many more...